Eprosartan Mesylate

CHEMBL1200987 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
520.6 g/mol
LogP
Phase
4

The mesylate salt form of eprosartan, this angiotensin receptor blocker relaxes blood vessels to lower blood pressure and reduce kidney strain. It is the standard formulation used in oral blood pressure treatment.

น้ำหนักโมเลกุล

520.6000 g/mol

TPSA

183.00 Ų

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O

InChI

InChI=1S/C23H24N2O4S.CH4O3S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27;1-5(2,3)4/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29);1H3,(H,2,3,4)/b18-12+;

Molecular Formula

C24H28N2O7S2

HBD / HBA

3 / 9

พันธะที่หมุนได้

10

อะตอมหนัก

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The mesylate salt form of eprosartan, this angiotensin receptor blocker relaxes blood vessels to lower blood pressure and reduce kidney strain. It is the standard formulation used in oral blood pressure treatment.

Yes, Eprosartan Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200987. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282474. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.